Table 2 - Nature Biotechnology

Table 2

Nature Biotechnology 22, 1230 - 1235 (2004)
doi:10.1038/nbt1004-1230

Towards quality assurance and harmonization of genetic testing services in the European Union

Dolores Ibarreta, Robert Elles, Jean-Jacques Cassiman, Emilio Rodriguez-Cerezo & Elisabeth Dequeker

Table 2 Regularly available EQA schemes stratified per organization level

	No. EQA^{^a} scheme organizers
	National	Regional or multinational	International	No. of participants per scheme (range)



Cystic fibrosis	1	3	2	6−210
Huntington disease	—	2	2	24−50
Duchenne and Becker Muscular dystrophy	1	1	2	19−27
Mitochondrial diseases	—	1	—	40
Familial breast and ovarian cancer	—	2	2	11−40
Fragile X syndrome	2	3	2	24−79
Hereditary hemochromatosis	2	—	2	24−97



^aExternal quality assessment.

Close window